-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Testicular Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Testicular Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Testicular Cancer Drug Details: CX-072 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin SSD in Hepatic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin SSD in Hepatic Encephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin SSD in Hepatic Encephalopathy Drug Details: Rifaximin soluble solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Methylnaltrexone Bromide in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Methylnaltrexone Bromide in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Methylnaltrexone Bromide in Head And...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin SSD in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin SSD in Sickle Cell Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin SSD in Sickle Cell Disease Drug Details: Rifaximin...
-
Product Insights
NewOphthalmic Imaging Equipment Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Ophthalmic Imaging Equipment Pipeline Market Report Overview Ophthalmic Imaging equipment is used to create images to aid in the diagnosis and treatment of eye diseases. The ophthalmic imaging equipment pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials....
-
Product Insights
NewBausch & Lomb Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Bausch & Lomb Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Bausch & Lomb Inc (Bausch & Lomb), a subsidiary of Bausch Health Companies Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It offers over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, lens care products, ophthalmic surgical devices and instruments. The company develops, manufactures and markets eye health products for the...
-
Product Insights
NewDecompensated Cirrhosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Decompensated Cirrhosis Clinical Trial Report Overview A total of 227 Decompensated Cirrhosis clinical trials were conducted as of April 2024. The Decompensated Cirrhosis Clinical Trial report provides an overview of the Decompensated Cirrhosis Clinical Trial scenario. This report provides top-line data relating to the clinical trials on Decompensated Cirrhosis. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Innovation Ranking
Innovation Ranking – Bausch Health Companies Inc
Bausch Health Companies Inc (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in...